Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Rising demand for precision medicine & groundbreaking innovations in RNA sequencing drive growth in oncology, drug discovery, & personalized therapies.

The supplement is designed to enhance muscle function and strength for dogs that are aging, active or undergoing muscle ...

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

In trials at University College London Hospitals (UCLH), an ASO is being used to target the mutated gene that results in the ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness ...

Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

Nonsense-mediated mRNA decay (NMD) is a crucial cellular mechanism that helps maintain the integrity of gene expression by degrading mRNAs that contain premature termination codons (PTCs).

Press releaseGenethon and Eukarÿs announce a strategic partnership to develop a breakthrough technology to reduce the biomanufacturing cost of ...

Benitec has a market cap of $250mn, $67.8mn in cash, and a cash runway of over 10 quarters, but faces risks due to its small ...